Skip to main content

DESCIFRANDO Y MODULANDO EL INTERACTOMA TRANSMEMBRANA DE LAS PROTEINAS BCL-2 COMO DIANA ANTITUMORAL

SAF2017-84689-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIÓN DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRÍNCIPE FELIPE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic

  • Galiana, Irene
  • Lozano-Torres, Beatriz
  • Sancho, Mónica
  • Alfonso-Navarro, María
  • Bisbal, Viviana
  • Serrano, Manuel
  • Orzaez, Mar
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] The induction of senescence produces a stable cell cycle arrest in cancer cells, thereby inhibiting tumor growth; however, the incomplete immune cell-mediated clearance of senescent cells may favor tumor relapse, limiting the long-term anti-tumorigenic effect of such drugs. A combination of senescence induction and the elimination of senescent cells may, therefore, represent an efficient means to inhibit tumor relapse. In this study, we explored the antitumor efficacy of a combinatory senogenic and targeted senolytic therapy in an immunocompetent orthotopic mouse model of the aggressive triple negative breast cancer subtype. Following palbociclib-induced senogenesis and senolysis by treatment with nano-encapsulated senolytic agent navitoclax, we observed inhibited tumor growth, reduced metastases, and a reduction in the systemic toxicity of navitoclax. We believe that this combination treatment approach may have relevance to other senescence-inducing chemotherapeutic drugs and additional tumor types. Significance: While the application of senescence inducers represents a successful treatment strategy in breast cancer patients, some patients still relapse, perhaps due to the subsequent accumulation of senescent cells in the body that can promote tumor recurrence. We now demonstrate that a combination treatment of a senescence inducer and a senolytic nanoparticle selectively eliminates senescent cells, delays tumor growth, and reduces metastases in a mouse model of aggressive breast cancer. Collectively, our results support targeted senolysis as a new therapeutic opportunity to improve outcomes in breast cancer patients., The M.O. laboratory members thank the financial support from the Spanish Government (project SAF2017-84689-R (MINECO/AEI/FEDER, EU)) and the Generalitat Valenciana (project PROMETEO/2019/065). The R.M. laboratory members thank the financial support from the Spanish Government (projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22 (MCUI/FEDER, EU) and the Generalitat Valenciana (project PROMETEO 2018/024). Both I.G. and B.L-T. are grateful to the Generalitat Valenciana and the Spanish Ministry of Economy, respectively, for their Ph.D. grants. I.G. would like to thank I. Borreda and J. Forteza and the Instituto Valenciano de Patologia for their special collaboration and F. Sancenon for his appreciated help
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Targeted-lung delivery of dexamethasone using gated mesoporous silica nanoparticles. A new therapeutic approach for acute lung injury treatment

  • García-Fernández, Alba|||0000-0002-8416-1674
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Sancho, Mónica
  • Bisbal, Viviana
  • Amorós, Pedro
  • Orzáez, Mar
[EN] Acute lung injury (ALI) is a critical inflammatory syndrome, characterized by increased diffuse inflammation and severe lung damage, which represents a clinical concern due to the high morbidity and mortality in critical patients. In last years, there has been a need to develop more effective treatments for ALI, and targeted drug delivery to inflamed lungs has become an attractive research field. Here, we present a nanodevice based on mesoporous silica nanoparticles loaded with dexamethasone (a glucocorticoid extensively used for ALI treatment) and capped with a peptide that targets the TNFR1 receptor expressed in pro-inflammatory macrophages (TNFR-Dex-MSNs) and avoids cargo leakage. TNFR-Dex-MSNs nanoparticles are preferentially internalized by pro-inflammatory macrophages, which overexpressed the TNFR1 receptor, with the subsequent cargo release upon the enzymatic hydrolysis of the capping peptide in lysosomes. Moreover, TNFR-Dex-MSNs are able to reduce the levels of TNF-alpha and IL-1I3 cytokines in activated pro-inflammatory M1 macrophages. The antiinflammatory effect of TNFR-Dex-MSNs is also tested in an in vivo ALI mice model. The administered nanodevice (intravenously by tail vein injection) accumulated in the injured lungs and the controlled dexamethasone release reduces markedly the inflammatory response (TNF-alpha IL-6 and IL-1I3 levels). The attenuation in lung damage, after treatment with TNFR-Dex-MSNs, is also confirmed by histopathological studies. Besides, the targeted-lung dexamethasone delivery results in a decrease of dexamethasone derived side-effects, suggesting that targeted nanoparticles can be used for therapy in ALI and could help to overcome the clinical limitations of current treatments., A. Garcia-Fernandez thanks the Spanish government for her FPU fellowship. The R. Martinez-Manez group is grateful to the Spanish Government (projects RTI2018-100910-B-C41 and RTI2018-101599-BC22-AR (MCUI/AEI/FEDER, UE) and the Generalitat Valencia (Project PROMETEO/2018/024) for support. M.Orz ' aez group thanks to the financial support from the Spanish Government (SAF2017-84689-R project MINECO/AEI/FEDER, UE) and the Generalitat Valenciana (project PROMETEO/2019/065). The authors would thank the Server Medical Art platform for using their templates to design some schemes. Would like to thank I. Borreda and J. Forteza from Instituto Valenciano de Patologia for its technical support in the histopathology analysis and Animal Facilities from Centro de Investigación Principe Felipe for its support in the animal research and procedures.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Horseradish Peroxidase-Functionalized Gold Nanoconjugates for Breast Cancer Treatment Based on Enzyme Prodrug Therapy

  • Vivo-Llorca, Gema
  • Diez-Sánchez, Paula
  • Orzáez, Mar
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Introduction: Breast cancer has the highest mortality rate among cancers in women. Patients suffering from certain breast cancers, such as triple-negative breast cancer (TNBC), lack effective treatments. This represents a clinical concern due to the associated poor prognosis and high mortality. As an approach to succeed over conventional therapy limitations, we present herein the design and evaluation of a novel nanodevice based on enzyme-functionalized gold nanoparticles to efficiently perform enzyme prodrug therapy (EPT) in breast cancer cells. Results: In particular, the enzyme horseradish peroxidase (HRP) which oxidizes the prodrug indole-3-acetic acid (IAA) to release toxic oxidative species is incorporated on gold nanoconjugates (HRP-AuNCs), obtaining an efficient nanoplatform for EPT. The nanodevice is biocompatible and effectively internalized by breast cancer cell lines. Remarkably, co-treatment with HRP-AuNCs and IAA (HRP-AuNCs/IAA) reduces the viability of breast cancer cells below 5%. Interestingly, 3D tumor models (multicellular tumor spheroid-like cultures) co-treated with HRP-AuNCs/IAA exhibit a 74% reduction of cell viability, whereas the free formulated components (HRP, IAA) have no effect. Conclusion: Altogether, our results demonstrate that the designed HRP-AuNCs nanoformulation shows a remarkable therapeutic performance. These findings might help to bypass the clinical limitations of current tumor enzyme therapies and advance towards the use of nanoformulations for EPT in breast cancer., Gema Vivo-Llorca thanks the Generalitat Valenciana for her fellowship ACIF/2017/072. Paula Díez thanks the Generalitat Valenciana for her contract APOSTD/2020/153 and to the Instituto de Salud Carlos III and the European Social Fund for the financial support "Sara Borrell", CD20/00120. Antoni Llopis-Lorente thanks funding from the European Union¿s Horizon 2020 research and innovation programme under grant agreement No 847675. Images were prepared using Servier Medical Art (https://smart.servier.com/). We thank the Spanish Government (project RTI2018-100910-B-C41 (MCUI/AEI/FEDER, UE); SAF2017-84689-R-B (MCUI/ AEI/FEDER, UE)) and the Generalitat Valenciana (project PROMETEO/2018/024 and PROMETEO/2019/065) for support. A pre-print version of this work was published as a chapter of the PhD thesis of the first author Gema VivoLlorca
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A renal clearable fluorogenic probe for in vivo ß-galactosidase activity detection during aging and senolysis

  • Rojas-Vázquez, Sara
  • Lozano-Torres, Beatriz
  • Galiana, Irene
  • Perez-Villalba, Ana
  • Martí-Rodrigo, Pablo
  • Palop, M. José
  • Domínguez, Marcia
  • Orzaez, Mar
  • Blandez, Juan F.
  • Fariñas, Isabel
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Accumulation of senescent cells with age leads to tissue dysfunction and related diseases. Their detection in vivo still constitutes a challenge in aging research. We describe the generation of a fluorogenic probe (sulfonic-Cy7Gal) based on a galactose derivative, to serve as substrate for beta-galactosidase, conjugated to a Cy7 fluorophore modified with sulfonic groups to enhance its ability to diffuse. When administered to male or female mice, beta-galactosidase cleaves the O-glycosidic bond, releasing the fluorophore that is ultimately excreted by the kidneys and can be measured in urine. The intensity of the recovered fluorophore reliably reflects an experimentally controlled load of cellular senescence and correlates with age-associated anxiety during aging and senolytic treatment. Interestingly, our findings with the probe indicate that the effects of senolysis are temporary if the treatment is discontinued. Our strategy may serve as a basis for developing fluorogenic platforms designed for easy longitudinal monitoring of enzymatic activities in biofluids. In vivo detection of cell senescence remains a challenge in aging research. This work introduces a novel fluorogenic probe for beta-Gal activity that is excreted in urine, providing a simple diagnosis method to estimate the systemic load of senescent cells during aging and senolytic interventions., We acknowledge the support of the Servicio Central de Soporte a la Investigacion Experimental of the Universitat de Valencia (SCSIE-UVEG). We are grateful to Biorender.com for the illustrations of mice used in the temporal scheme of the senolytic treatment in Figs. 5 and 6 (agreement number: IX264V4WHR). We thank Dr. D. Munoz-Espin for providing us with siRNAs for knock-down experiments and Dr. S. Gil for his assistance in NMR analysis. Work in the laboratory of R. M.-M was supported by grants from the Spanish Government (PID2021-126304OB-C41) and the Generalitat Valenciana (PROMETEO CIPROM/2021/007). Work in the laboratory of I.F. was supported by grants from the Spanish Government (PID2020-117937GB-I00, RED2018-102723-T, and CIBERNED CB06/05/ 0086) and Generalitat Valenciana (PROMETEO/2021/028). We also acknowledge the financial support from the Spanish Government (SAF2017-84689-R project MINECO/AEI/FEDER, UE) and the Generalitat Valenciana (project PROMETEO/2019/065) to M. O. A. P. V. was also founded by CITSAM (2021-283-001). S. R.-V. (FPU 16/03714) and B. L.-T. (FPU15/02707) were recipients of FPU predoctoral contracts from the Spanish Ministerio de Educacion; P. M-R. was the recipient of a predoctoral contract (LCF/BQ/DE18/11670015) from Fundacio la Caixa; J. F. B. was the recipient of a postdoctoral contract (PAID-10-17) of the Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of NLRP3 PYD Homo-Oligomerization Inhibitors with Anti-Inflammatory Activity

  • Moasses Ghafary, Soroush
  • Lotfollahzadeh, Shima
  • Sancho, Mónica
  • Serrano-Candelas, Eva
  • Karami, Fatemeh
  • Barigye, Stephen J.
  • Fernández-Pérez, Iván
  • Gozalbes, Rafael
  • Nikkhah, Maryam
  • Orzáez, Mar
  • Hosseinkhani, Saman
  • Soriano-Teruel, Paula
[EN] Inflammasomes are multiprotein complexes that represent critical elements of the inflammatory response. The dysregulation of the best-characterized complex, the NLRP3 inflammasome, has been linked to the pathogenesis of diseases such as multiple sclerosis, type 2 diabetes mellitus, Alzheimer's disease, and cancer. While there exist molecular inhibitors specific for the various components of inflammasome complexes, no currently reported inhibitors specifically target NLRP3(PYD) homo-oligomerization. In the present study, we describe the identification of QM380 and QM381 as NLRP3(PYD) homo-oligomerization inhibitors after screening small molecules from the MyriaScreen library using a split-luciferase complementation assay. Our results demonstrate that these NLRP3(PYD) inhibitors interfere with ASC speck formation, inhibit pro-inflammatory cytokine IL1-beta release, and decrease pyroptotic cell death. We employed spectroscopic techniques and computational docking analyses with QM380 and QM381 and the PYD domain to confirm the experimental results and predict possible mechanisms underlying the inhibition of NLRP3(PYD) homo-interactions., This research was funded by EC-funded RISE (EPIC 690939), Spanish Ministry of Economy and Competitiveness, FEDER (SAF2017-84689-R), Generalitat Valenciana (PROMETEO/2019/065), research council of Tarbiat Modares University (#IG/39803).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Real-Time In Vivo Detection of Cellular Senescence through the Controlled Release of the NIR Fluorescent Dye Nile Blue

  • Lozano-Torres, Beatriz
  • Blandez, Juan F.
  • Galiana, Irene
  • Alfonso-Navarro, María
  • Orzáez, Mar
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] In vivo detection of cellular senescence is accomplished by using mesoporous silica nanoparticles loaded with the NIR-FDA approved Nile blue (NB) dye and capped with a galactohexasaccharide (S3). NB emission at 672 nm is highly quenched inside S3, yet a remarkable emission enhancement is observed upon cap hydrolysis in the presence of beta-galactosidase and dye release. The efficacy of the probe to detect cellular senescence is tested in vitro in melanoma SK-Mel-103 and breast cancer 4T1 cells and in vivo in palbociclib-treated BALB/cByJ mice bearing breast cancer tumor., R.M. thanks financial support from the Spanish Government (RTI2018-100910-B-C41 and RTI2018-101599-B-C22 (MCUI/AEI/FEDER, UE)) and the Generalitat Valenciana (PROMETEO 2018/024). M.O. thanks the financial support from SAF2017-84689-R project and MINECO/AEI/FEDER, UE and the Generalitat Valenciana (PROMETEO/2019/065). B.L.-T. is grateful to the Spanish Ministry of Economy for her PhD grant. I.G. thanks her contract from IDM. J.F.-B. and M.A. thank the UPV for their postdoctoral fellowship.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

  • Candela-Noguera, Vicente
  • Aznar, Elena|||0000-0003-0361-3876
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Vivo-Llorca, Gema
  • Díaz de Greñu, Borja
  • Alfonso, María
  • Orzáez, Mar
[EN] We report herein a gene-directed enzyme prodrug therapy (GDEPT) system using gated mesoporous silica nanoparticles (MSNs) in an attempt to combine the reduction of side effects characteristic of GDEPT with improved pharmacokinetics promoted by gated MSNs. The system consists of the transfection of cancer cells with a plasmid controlled by the cytomegalovirus promoter, which promotes ß-galactosidase (ß-gal) expression from the bacterial gene lacZ (CMV-lacZ). Moreover, dendrimer-like mesoporous silica nanoparticles (DMSNs) are loaded with the prodrug doxorubicin modified with a galactose unit through a self-immolative group (DOXO-Gal) and modified with a disulfide-containing polyethyleneglycol gatekeeper. Once in tumor cells, the reducing environment induces disulfide bond rupture in the gatekeeper with the subsequent DOXO-Gal delivery, which is enzymatically converted by ß-gal into the cytotoxic doxorubicin drug, causing cell death. The combined treatment of the pair enzyme/DMSNs-prodrug are more effective in killing cells than the free prodrug DOXO-Gal alone in cells transfected with ß-gal., This research was funded by the Spanish Government (projects RTI2018-100910-B-C41, RTI2018-101599-B-C22 and SAF2017-84689-R (MCUI/FEDER, EU)) and the Generalitat Valenciana (projects PROMETEO 2018/024 and PROMETEO/2019/065). Vicente Candela-Noguera thanks the Spanish Government for his fellowship (FPU15/02753). Gema Vivo-Llorca thanks the Generalitat Valenciana for her fellowship (ACIF/2017/072).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

MUC1 Aptamer-Capped Mesoporous Silica Nanoparticles for Navitoclax Resistance Overcoming in Triple-Negative Breast Cancer

  • Vivo-Llorca, Gema
  • Alfonso-Navarro, María
  • Orzáez, Mar
  • Candela-Noguera, Vicente
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. In the last years, navitoclax has emerged as a possible treatment for TNBC. Nevertheless, rapid navitoclax resistance onset has been observed thorough Mcl-1 overexpression. As a strategy to overcome Mcl-1-mediated resistance, herein we present a controlled drug co-delivery system based on mesoporous silica nanoparticles (MSNs) targeted to TNBC cells. The nanocarrier is loaded with navitoclax and the Mcl-1 inhibitor S63845 and capped with a MUC1-targeting aptamer (apMUC1-MSNs(Nav/S63845)). The apMUC1-capped nanoparticles effectively target TNBC cell lines and successfully induce apoptosis, overcoming navitoclax resistance. Moreover, navitoclax encapsulation protects platelets against apoptosis. These results point apMUC1-gated MSNs as suitable BH3 mimetics nanocarriers in the targeted treatment of MUC1-expressing TNBC., Gema Vivo-Llorca thanks the Generalitat Valenciana for her fellowship ACIF/2017/072. Vicente Candela-Noguera thanks the Spanish Government for his fellowship FPU15/02753. We would like to thank Servier for the workart used in the figures of this manuscript (Servier Medical Art ). We thank the Spanish Government (project RTI2018-100910-B-C41 (MCUI/AEI/FEDER, UE); SAF2017-84689-R-B (MCUI/AEI/FEDER, UE)) and the Generalitat Valenciana (project PROMETEO/2018/024 and PROMETEO/2019/065) for support.